Secondary Progressive Multiple Sclerosis (SPMS) - Disease Overview, Epidemiology and Drug Overview

  • ID: 4431982
  • Report
  • Region: Global
  • Pharma Scroll
1 of 3

The report provides an overview of secondary progressive multiple sclerosis (SPMS) disease indication in detail, highlights the SPMS epidemiology in the present scenario and includes forecasts in key geographies across the globe. The report elaborates on the drugs prescribed and expected to be prescribed in SPMS by  physicians. The report starts with the basic definition, causes and symptoms of Multiple Sclerosis (MS) and further details the types of Multiple Sclerosis disease indication.The report elaborates on the Secondary Progressive Multiple Sclerosis disease indication detailing the definition, causes, profile of a SPMS patient, symptoms of a SPMS patient, and disease progression in a SPMS patient. The report further highlights the multiple methods through which the patient can be diagnosed for SPMS.

The middle part of the report consists of SPMS epidemiology and prevalence in the key geographies across the globe such as the US, UK, Germany, Italy, France, Spain and Japan. The epidemiology for SPMS indication across key geographies has been forecasted up to 2024.

The latter part of the report highlights the importance of factors influencing physician prescription decisions in SPMS such as efficacy factors, tolerability factors, monitoring requirements and pricing factors. The report further details the drugs prescribed or expected to be prescribed in SPMS by the physicians in terms of details about the formulation, molecule, mode of administration and MoA of the drugs, their patent and trial details and the expected impact of drug in the SPMS market.

Note: Product cover images may vary from those shown
2 of 3

1. Multiple Sclerosis Definition

2. Types of Multiple Sclerosis

a. Relapsing Remitting MS

b. Secondary Progressive MS

c. Primary Progressive MS

d. Progressive Relapsing MS

3. Secondary Progressive Relapsing MS Defined

4. Causes of SPMS

5. Profile of SPMS Patient

6. Symptoms of SPMS

7. Disease progression and impact on QoL

8. Disease Diagnosis

a. Disease diagnosis through symptoms

b. Disease diagnosis through medical tests

9. Disease Epidemiology

a. US Epidemiology

b. UK Epidemiolog

c. Germany Epidemiology

d. Italy Epidemiology

e. France Epidemiology

f. Spain Epidemiology

g. Japan Epidemiology

10.Factors impacting a physician’s prescription decision

a. Efficacy

b. Tolerability and Safety

c. Monitoring Requirements

d. Pricing and Reimbursement

11.Disease Modifying Therapies for SPMS

a. Laquinimod

i. About the Product

ii. Patent and Trial Details

iii. Impact of Laquinimod

b. Lemtrada

i. About the Product

ii. Patent and Trial Details

iii. Impact of Lemtrada

c. Masitinib

i. About the Product

ii. Patent and Trial Details

iii. Impact of Masitinib

d. Ocrelizumab

i. About the Product

ii. Patent and Trial Details

iii. Impact of Ocrelizumab

e. Tysabri

i. About the Product

ii. Patent and Trial Details

iii. Impact of Tysabri

f. Siponimod

i. About the Product

ii. Patent and Trial Details

iii. Impact of Siponimod

g. Zinbryta

i. About the Product

ii. Patent and Trial Details

iii. Impact of Zinbryta

h. Mitoxantrone

i. About the Product

ii. Patent and Trial Details

iii. Impact of Mitoxantrone

i. Ponesimod

i. About the Produc

ii. Patent and Trial Details

iii. Impact of Ponesimod

Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll